Anxiety Symptoms In People Research Articles

The Impact on Anxiety Symptoms of an Immersive Virtual Reality Remediation Program in Bipolar Disorders: A Randomized Clinical Trial.

Background: The objective of this work is to investigate the effectiveness of a cognitive remediation intervention on anxiety symptoms in people with bipolar disorder and the therapeutic effect on people whose anxiety symptoms were above the threshold for a screener and whose comorbidity could be identified as an anxiety disorder. Methods: The experimental intervention included 24 sessions (around 45 min each), two for each week over three months. The entire program was inspired by user-centered rehabilitation principles in a recovery-oriented perspective and an approach to bipolar disorder in an evolutionary and non-discriminating vision. The primary outcomes measure the score of the Zung Self-Rating Anxiety Scale (SAS), hypothesizing a higher decrease in the experimental group than in the control group. The survey has been conducted per the CONSORT guidelines for feasibility studies. Results: We evaluate a decrease in the overall SAS score from T0 to T1 to be higher in the experimental group compared to the control group, indicating an improvement in anxiety symptoms (p < 0.0001). Conclusions: The study suggests that virtual reality could have a role in treating anxiety symptoms and disorders in young adults with bipolar disorders or anxiety symptoms in people with hyperactivity and novelty-seeking behaviorsunder stress and high risk for bipolar disorder.

Anxiety Symptoms and Disease Severity in Parkinson Disease.

BACKGROUND: Anxiety is prevalent in Parkinson disease (PD), negatively affecting quality of life for patients and their families. Targeted anxiety interventions are needed that account for variables such as disease severity; however, there is insufficient evidence regarding the trajectory of anxiety along the disease course. OBJECTIVE: The aim of this study was to investigate the association between disease severity and anxiety symptoms in a PD sample. METHODS: This descriptive study used secondary data analyses of data from a web-based survey study of individuals with PD in the United States. Participants were 21 years or older, had access to the Internet, and were given a diagnosis of PD (N = 72). We performed multiple regression analyses to assess the relationship between patient-reported disease severity and anxiety symptoms. RESULTS: There was a statistically significant association between disease severity and anxiety symptoms in people with PD, after controlling for all 5 explanatory variables (sex, age, wearing off, disease severity, and disease duration) ( P < .001). Age and wearing off PD medication also had statistically significant, although smaller, effects on anxiety symptoms ( P < .05). CONCLUSION: Disease severity was related to increased anxiety symptoms among individuals with PD. Anxiety intervention research is needed, and future studies should account for variations in disease severity and medication effects in both intervention and study design.

Nurse-Implemented Music Therapy to Reduce Anxiety in Community-Dwelling Individuals with Severe Mental Illness: A Pilot Study.

Anxiety is an important and recurrent problem in people with severe mental illness (SMI). The aim of this work is to measure the effectiveness of the Music Therapy nursing intervention in reducing anxiety in outpatients diagnosed with SMI (bipolar disorder and schizophrenia). The intervention was structured over five weeks (ten 1-h sessions, twice weekly). Objective measures (blood pressure, heart rate, and respiratory rate) and subjective measures (anxiety response and the subjective perception of relaxation) were taken before and after every session. Our results show that this nursing intervention entails an objective reduction of the respiratory rate ((-4.5, -0.5) breaths per minute), the heart rate ((-5.80, -2.13) bpm), and it evidences a reduction in the subjective perception of anxiety (16.08% mean reduction in state anxiety). Considering all the sessions, the subjective perception of relaxation increased 97.33% of the time. This study provides evidence that the Music Therapy intervention can effectively promote relaxation and reduce anxiety symptoms in people with SMI. This study was retrospectively registered at Clinical Trials with Protocol Identifier NCT06315049.

Association between the COVID-19 pandemic and psychiatric symptoms in people with preexisting obsessive-compulsive, eating, anxiety, and mood disorders: a systematic review and meta-analysis of before-after studies.

To determine whether the coronavirus disease 2019 (COVID-19) pandemic was associated with a change in psychiatric symptoms in people with preexisting obsessive-compulsive, eating, anxiety, and mood disorders compared to their prepandemic levels. We searched MEDLINE, CINAHL, PsycINFO, and Embase from inception until February 16, 2022. Studies were included if they reported prepandemic and during-pandemic psychiatric symptoms, using validated scales, in people with preexisting mood, anxiety, eating, or obsessive-compulsive disorders. Two reviewers independently screened studies, extracted data, and assessed evidence certainty. Random-effects meta-analyses were conducted. Effect sizes were reported as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Eighteen studies from 10 countries were included. Of the 4465 included participants, 68% were female and the average age was 43 years. Mood and obsessive-compulsive disorders were the most studied disorders. During-pandemic psychiatric measurements were usually collected during nationwide lockdown. Obsessive-compulsive symptoms worsened among people with obsessive-compulsive and related disorders, with a moderate effect size (N = 474 [six studies], SMD = -0.45 [95% CI, -0.82 to -0.08], I2 = 83%; very low certainty). We found a small association between the COVID-19 pandemic and reduced anxiety symptoms in people with mood, anxiety, obsessive-compulsive, and eating disorders (N = 3738 [six studies], SMD = 0.11 [95% CI, 0.02-0.19], I2 = 63%; very low certainty). No change in loneliness, depressive, or problematic eating symptoms was found. People with obsessive-compulsive and related disorders may benefit from additional monitoring during the COVID-19 pandemic and possibly future pandemics. Other psychiatric symptoms were stable in people with the specific disorders studied. Overall, evidence certainty was very low.

The effectiveness of mindfulness-based cognitive therapy for social anxiety symptoms in people living with alopecia areata: a single-group case-series design.

Alopecia areata (AA) is an immunological disorder characterised by hair loss. Individuals with AA report high levels of social anxiety. One intervention that holds potential for reducing social anxiety in individuals with AA is mindfulness-based cognitive therapy (MBCT). Our key aim was to investigate whether MBCT reduces social anxiety in individuals with AA. The study also investigated whether MBCT reduces depression, general anxiety, and increases quality of life and increases trait mindfulness in individuals with AA. Five participants with AA took part in an 8-session in-person MBCT intervention. A multiple-baseline single-group case series design was adopted. Idiographic measures of social anxiety were measured each day from baseline, through intervention, to follow-up. Standardised questionnaires of trait mindfulness, social anxiety, depression, anxiety, and quality of life were completed at baseline, post-intervention, and at 4-week follow-up. All participants completed the MBCT course, but one participant was excluded from the idiographic analysis due to a high amount of missing data. The remaining four participants demonstrated reductions in idiographic measures of social anxiety from baseline to follow-up. These effects were larger between baseline and follow-up, than between baseline and post-intervention. Two participants demonstrated significant improvement in standardised measures of wellbeing from baseline to follow-up - they also practised mindfulness most regularly at home between sessions. MBCT may be effective in reducing social anxiety and improving wellbeing in individuals with AA, although this might be dependent on the extent to which participants regularly practise mindfulness exercises.

Cannabidiol for neuropsychiatric symptoms in Alzheimer’s dementia

AbstractBackgroundBehavioural and Psychological Symptoms of Dementia (BPSD) in people with Alzheimer’s disease (AD) is particularly distressing to patients and carers. There are currently no licensed medications for BPSD, and the current available treatments have limited benefits and greater risk for side effects. There is therefore a considerable unmet clinical need for interventions that are safe, well‐tolerated and effective for treating BPSD in AD. Cannabidiol (CBD), a non‐addictive substance present in cannabis shows promise for treating psychotic and anxiety symptoms in people without dementia and is generally safe and well‐tolerated in elderly. However, its efficacy, safety and tolerability need to be systematically tested in elderly with dementia. We aimed to evaluate acceptability and tolerability of CBD as treatment for BPSD in patients with AD.MethodsWe are conducting a double‐blind, parallel group, placebo‐controlled pragmatic randomized controlled feasibility trial (EudraCT Number ‐ 2019‐002106‐52) and recruiting AD patients with BPSD within Mental Health for Older Adults services, South London and Maudsley NHS trust, United Kingdom. Half of the participants receive 600 mg of CBD orally once a day over 6 weeks and the other half receive a placebo, in addition to their usual treatment for 6 weeks. Clinical data collected includes measures of cognition, Clinical Dementia Rating for staging, behaviour symptoms on Neuropsychiatric Inventory (NPI), global functioning, Quality of Life for patients and carer’s burden. Tolerability is assessed by self‐report of side‐effects, and side‐effect rating scale.ResultsOf the participants recruited and randomised so far, there have been no withdrawals or serious adverse events. The study is ongoing and due for completion at the end of April 2022, following which we will have the data to analyse and present the findings at the July 2022 conference.ConclusionsCBD has been generally acceptable and safe for people with AD with BPSD. The final analysis and findings related to adverse events, and changes in clinical measures for the groups (CBD treatment versus placebo) including BPSD, cognition etc. will be presented at the conference.

IMPROVEMENT OF CAREGIVER MASTERY IS RELATED TO DECREASED ANXIETY AMONG PEOPLE LIVING WITH COGNITIVE IMPAIRMENT

Abstract Anxiety is common and distressing in people living with cognitive impairment. High caregiver mastery, a positive view of one’s ability to provide care, is known to be protective against anxiety in people whom they are caring for. However, the longitudinal relationship between caregiver mastery and anxiety is unknown. Our objective was to examine whether improvement in caregiver mastery was related to decrease in anxiety in people living with cognitive impairment. This was a secondary data analyses using Healthy Patterns Clinical Trial (NCT03682185), an RCT of a home-based activity intervention designed to improve circadian rhythm disorders in people living with cognitive impairment. A total of 158 participants with cognitive impairment who provided data at both pretest (T1) and posttest (T2) were analyzed. Measures included Caregiver Mastery Scale and Neuropsychiatric Inventory. We used linear regression analyses to examine the relationship between changes in caregiver mastery and changes in anxiety. The sample was primarily female (66.7%), Black (63.1%), with mean age 73.3±8.4. The mean change of anxiety frequency (T2-T1) was -0.2±1.0; anxiety frequency decreased over time. The mean change of caregiver mastery (T2-T1) was 0.4± 3.0; caregiver mastery improved over time. After controlling for age, cognition, changes in sleep impairments, changes in depression, and intervention group assignment, improvement of caregiver mastery over time (B=-0.087, SE=0.035, t=-2.51, p=0.013) was related to decreased anxiety frequency over time (R2= 0.112, F=2.31, p= 0.039). Interventions to improve caregiver mastery may alleviate anxiety symptoms in people living with cognitive impairment. Additional research and practice implications will be discussed.

Effect of decrease of physical activity on depression and anxiety after the COVID-19 lockdown: A survey study.

We focused on changes in the amount of physical activity (PA) and depression and anxiety symptoms in people, who were previously regularly physically active, as they were all members of fitness centers at time of lockdown because of COVID-19. We sampled 150 fitness center members, tested individually in facilities of fitness centers. Depression and anxiety were measured with subscales of Personality Assessment Inventory (PAI) and PA was measured with global physical activity questionnaire (GPAQ). We found that depression (t = -1.97; p < 0.05) and anxiety (t = -2.66; p < 0.05) was more present in female participants than male participants, single participants experienced more depression (t = 2.04; p < 0.05) than participants in relationship, unemployed participants experienced more depression (F = 3,24; p < 0.05) and anxiety (F = 5,32; p < 0.01) than employed participants and participants with lower levels of education experienced higher levels of affective depression (F = 3,42; p < 0.05) and physiological anxiety (F = 3,72; p < 0.05) than participants with higher levels of education. Finally, we found that mental health can be influenced by changes in amount of movement-both anxiety (p < 0.05) and depression (p < 0.05) (in whole and its specific dimensions) increased for male participants when there is less strenuous work-related activity, less walking, or cycling to work and when they would spend more time each day sitting. For female participants, affective depression (t = 3.78; p < 0.01) and anxiety (t = 3.23; p < 0.01) increased with increased sitting time. Ex-competitive athletes are particularly immune to anxiety (t = -2.18; p < 0.05) and depression (t = -2.09; p < 0.05). As in some previous studies, our results show that because of lockdown, the most endangered groups for mood disorders are women, singles, unemployed and students, uneducated people and those, who had less PA, and more sitting time. Additionally, those who had some sport competitive history are less endangered for depression and anxiety. Isolation has great impact on mental health, the most effective solution to stress relief and anxiety is physical exercise, which was limited or non-existent in the time of pandemic. Ex-professional athletes are especially immune to anxiety and depression in events such as COVID-19 lockdown. For future studies we recommend focusing on likelihood of increased depression and anxiety levels in individuals, who were physically active before the isolation period.

Multimorbidity, depression with anxiety symptoms, and decrements in health in 47 low- and middle-income countries

BackgroundComorbid depression and anxiety is associated with worse health outcomes compared to depression or anxiety occurring in isolation, but there is little data on its association with multimorbidity. Thus, we investigated this association across 47 low- and middle-income countries, and further explored whether having anxiety symptoms in addition to depression is associated with significant declines in health outcomes among those with multimorbidity. MethodsCross-sectional, predominantly nationally representative, community-based data were analyzed from the World Health Survey. DSM-IV depression was assessed with the Composite International Diagnostic Interview. Anxiety symptoms referred to severe/extreme problems with worry or anxiety. Ten chronic conditions and health status across five domains (cognition, interpersonal activities, sleep/energy, self-care, pain/discomfort) were assessed. Multivariable regression analyses conducted. ResultsData included 237,952 adults aged ≥18 years [mean age (SD) 38.4 (16.0); 50.8 % females]. Compared to no chronic conditions, 2 (OR = 6.86; 95%CI = 5.59–8.42), 3 (OR = 12.33; 95%CI = 9.72–15.63), and ≥4 (OR = 26.55; 95%CI = 20.21–35.17) chronic conditions were associated with significantly higher odds for comorbid depression/anxiety symptoms (vs. no depression or anxiety symptoms) in the multinomial logistic regression model. Among those with depression and multimorbidity, anxiety symptoms were associated with significantly worse health status across all domains. LimitationsCross-sectional design, depression and anxiety symptoms were not based on a clinical assessment. ConclusionsComorbid depression/anxiety is common in people with multimorbidity, and anxiety symptoms in people with depression and multimorbidity signify worse health status. Future studies should assess the utility of screening for and treating comorbid depression/anxiety in patients with multimorbidity in terms of clinical outcomes.

Diabetes Distress, Depressive Symptoms, and Anxiety Symptoms in People With Type 2 Diabetes: A Network Analysis Approach to Understanding Comorbidity

In this study, we aimed to explore interactions between individual items that assess diabetes distress, depressive symptoms, and anxiety symptoms in a cohort of adults with type 2 diabetes using network analysis. Participants (N = 1,796) were from the Montreal Evaluation of Diabetes Treatment (EDIT) study from Quebec, Canada. A network of diabetes distress was estimated using the 17 items of the Diabetes Distress Scale (DDS-17). A second network was estimated using the DDS-17 items, the nine items of the Patient Health Questionnaire (PHQ-9), and the seven items of the Generalized Anxiety Disorder Assessment (GAD-7). Network analysis was used to identify central items, clusters of items, and items that may act as bridges between diabetes distress, depressive symptoms, and anxiety symptoms. Regimen-related and physician-related problems were among the most central (highly connected) and influential (most positive connections) in the diabetes distress network. The depressive symptom of failure was found to be a potential bridge between depression and diabetes distress, being highly connected to diabetes distress items. The anxiety symptoms of worrying too much, uncontrollable worry, and trouble relaxing were identified as bridges linking both anxiety and depressive items and anxiety and diabetes distress items, respectively. Regimen-related and physician-related diabetes-specific problems may be important in contributing to the development and maintenance of diabetes distress. Feelings of failure and worry are potentially strong candidates for explaining comorbidity. These individual diabetes-specific problems and mental health symptoms could hold promise for targeted interventions for people with type 2 diabetes.

Mental Health Disturbance after a Major Earthquake in Northern Peru: A Preliminary, Cross-Sectional Study

Little has been studied in Peru on the mental health repercussions after a major earthquake. We aimed to explore the factors associated with depressive and anxiety symptoms in people who experienced a 6.1 magnitude earthquake in Piura, Peru, on 30 July 2021. A preliminary cross-sectional study was conducted in the general population between August–September 2021. An online questionnaire was provided using PHQ-9, GAD-7, and other relevant measures. Generalized linear models were applied. Of the 177 participants, the median age was 22 years, the majority were female (56%), and many experienced depressive (52%) or anxiety symptoms (52%). Presence of depressive symptoms was associated with a personal history of mental disorder, moderate housing damage, social/material support from politicians, moderate food insecurity, and insomnia. Presence of anxiety symptoms was associated with physical injury caused by the earthquake, mild food insecurity, and insomnia. The development of depressive and anxiety symptoms following the 2021 earthquake experienced in Piura depended on multiple individual and socioeconomic factors. Additional studies should reinforce the factors identified here given the methodological limitations, such as the study design, sampling method, and sample size. This would lead to effective intervention measures to mitigate the impact of earthquakes on mental health.

Correlation of Depression and Anxiety in Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital

Context: People with type 2 diabetes are more likely than the general population to have depressive And anxiety symptoms. Type 2 diabetics are being studied for depression and anxiety. Aim: To investigate the Prevalence and correlates of Depression and Anxiety in Type 2 Diabetes Mellitus Patients. Settings and Design: The Department of Endocrine and Medicine at Vijaya Hospital in Belagavi, South India, did a descriptive research. Methods and Materials: In a study on depression and anxiety, 384 people with type 2 diabetes were administered the Hospital Anxiety and Depression Scale (HADS). Statistical analysis used: Descriptive and inferential statistical analysis were done using SPSS software. Results: Depression and anxiety were found in 32.56% and 37.76% of the 384 patients assessed, respectively. P = 0.0001 showed a strong connection between anxiety and depressive symptoms (r = 0.7046) in this study. Type 2 diabetes duration, type of therapy and HADS-Anxiety were known to have a significant association. HADS-Depression revealed a significant association with age, qualification, type 2 diabetes duration, and treatment type (P &lt; 0.05) in the same way as HADS-Depression does. Conclusion: According to the findings of this study, anxiety and sadness are widespread among people with type 2 diabetes. Furthermore, a strong link between depression and anxiety was observed across a wide range of variables. Depression and anxiety symptoms in people with type 2 diabetes should be assessed and treated on a frequent basis.

An Anxious Heart: The Relation Between Cardiovascular Disease and Prevalence of Anxiety Symptoms

IntroductionCardiovascular disease represent the leading cause of death worldwide, and is also responsible for the consumption of many medical resources, work absenteeism and worse Quality of Life. On the other hand, psychiatric diseases have recently gained more relevance worldwide as one of the principal causes of disability.ObjectivesEvaluate a possible relationship between cardiovascular risk factors (CVRF) and anxious or depressive symptoms.MethodsObservational and cross-sectional study in a non-probabilistic and convenience sample, composed by patients followed on five primary healthcare facilites, who voluntarily accepted to answer the questionnaire through an interview, between July 2020 and January 2021. After an informed consent, a questionnaire was carried out including sociodemographic characterization, presence of cardiovascular disease and/or cardiovascular risk factors and the Portuguese version of HADS. Descriptive and inferential statistics were performed, using Mann-Whitney U test. A value of p&lt;0,05 was considered statistically significant.ResultsSample of 179 people, 53,1% female, with an average age of 51,05 ± 22,02 years, in which 57,5% had one or more CVRF and 59,8% had CVD and/or CVFR and the most prevalent CVRF were hypertension (48%) and dyslipidemia (43,6%). There was a statistically significant relationship between diabetes and anxiety (p&lt;0,05).ConclusionsThere was a greater prevalence of anxiety symptoms in people with diabetes compared to people without diabetes. This suggests the importance of giving attention to anxiety in patients with diabetes, given the relevance of this comorbidity in their quality of life. The main limitation of the study is related with the sample size.DisclosureNo significant relationships.

Current Cigarette Smoking Is Associated With a High Seizure Frequency and Anxiety Symptoms in People With Epilepsy.

PurposeThis study aims to answer the following questions: how many people with epilepsy (PWE) have cigarette smoking habits? Which demographic or clinical characteristics are associated with cigarette smoking? Is cigarette smoking related to depressive and anxiety symptoms in PWE?MethodsA total of 524 PWE were included in the final analysis. Demographic and clinical data were gathered and recorded. Smoking status was identified. The associations of smoking status with the clinical features of epilepsy and depressive and anxiety symptoms were evaluated by logistic regression models.ResultsThe overall prevalence of cigarette smoking was 23.5% (123 PWE) in this sample. In the multivariate logistic regression model, men (adjusted OR = 10.414, 95% CI: 5.552–19.535, P < 0.001), high seizure frequency (adjusted OR = 1.474, 95% CI: 1.043–2.084, P = 0.028), and anxiety symptoms (adjusted OR = 2.473, 95% CI: 1.483–4.112, P = 0.001) were shown to have independent associations with cigarette smoking in PWE.ConclusionOur findings suggested that the overall prevalence of cigarette smoking was 23.5% in adults with epilepsy, which is slightly lower than that (26.6%) in general adults in China. In the present study, cigarette smoking was associated with men, high seizure frequency, and anxiety symptoms in PWE. Further prospective clinical studies with larger sample sizes are required to confirm our findings.

Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial.

Individuals with a cocaine use disorder (CUD) are more likely to present anxiety, which in turn negatively impacts substance use outcomes. Some evidence suggests that cannabidiol (CBD) presents anxiolytic properties and could be a treatment for substance use disorders. This study explores CBD's effect on stress biomarker (cortisol) and anxiety symptoms in people with CUD. Exploratory analyses were conducted using data from a randomized, double-blind, placebo-controlled trial evaluating CBD's efficacy to treat CUD. We randomized 78 individuals with CUD into receiving a daily oral dose up to 800 mg CBD (n = 40) or placebo (n = 38). The trial was divided into 2 phases: an inpatient detoxification lasting 10 days and an outpatient follow-up lasting 12 weeks. Anxiety symptoms and stress response were assessed using a visual analog scale, the Beck Anxiety Inventory, and cortisol levels at multiple time points throughout the study. We also measured anxiety after a stressful and a cocaine-cue scenarios. We used generalized estimating equations models and multiple linear regression to assess CBD's effects on anxiety and cortisol levels. Both treatment groups had similar mean anxiety scores according to the Beck Anxiety Inventory ( P = 0.27) and the visual analog scale ( P = 0.18). CBD did not decrease anxiety after a stressful ( P = 0.14) and a cocaine ( P = 0.885) scenarios compared with placebo. No statistically significant group difference was found in cortisol levels ( P = 0.76). We found no evidence for 800 mg of CBD to be more efficacious than placebo for modulating anxiety symptoms and cortisol levels in individuals with CUD.

Management of Psychiatric Disorders with HIV and Dermatological Disorders.

Management of Psychiatric Disorders with HIV and Dermatological Disorders.

Revisiting Treatment Options for Depressed Patients with Generalised Anxiety Disorder.

Symptoms of anxiety and depression often coexist, and evidence suggests that this has a genetic basis, among other possible causes. However, the current classification of comorbid generalised anxiety disorder (GAD) and depression (anxious depression) in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition; DSM-5) does not fully reflect the high prevalence of anxiety symptoms in people with depression and the International Classification of Diseases (10th and 11th revisions) has tended to identify anxious depression with minor disorders seen in primary care. As a result, few dedicated therapeutic trials have been conducted in patients with anxious depression, and specific treatment guidelines and recommendations are lacking. Fortunately, there is considerable therapeutic overlap between anxiety and depression, such that many agents with antidepressant efficacy are also effective for symptoms of GAD. The initial treatment of a patient with depression and symptoms of anxiety should be with an agent that is approved for both major depressive disorder and GAD, such as a selective serotonin reuptake inhibitor. There is an obvious need for greater recognition of anxious depression in order to boost the volume of high-quality clinical data, which should translate over time into better, more specific treatment recommendations and improved outcomes.

Network of depression and anxiety symptoms in patients with epilepsy

PurposeDepression and anxiety are often comorbid in people with epilepsy. Network models consider this comorbidity as an interacting system of depressive and anxiety symptoms. The present study investigates the network structure of depressive and anxiety symptoms in people with epilepsy and aims to identify the central and bridge symptoms to provide suggestions for the prevention of and intervention for depression-anxiety comorbidity in patients with epilepsy. MethodsA total of 313 patients with epilepsy were enrolled in our study. Anxiety symptoms were evaluated with the Generalized Anxiety Disorder 7-Item questionnaire. Depressive symptoms were evaluated with the Patient Health Questionnaire-9. Network analyses were used for the statistical analysis. ResultsThe findings indicated that ten edges with the strongest regularized partial correlations existed in the network. Six were among depressive symptoms, such as “sleep difficulties” with “fatigue” and “ feeling of worthlessness” with “thoughts of death”. Four were among anxiety symptoms, such as “nervousness or anxiety” with “uncontrollable worry” and “uncontrollable worry” with “worry too much”. Those strongest edges had no connection linking anxiety and depressive symptoms. The symptoms “depressed or sad mood”, “trouble relaxing” and “uncontrollable worry” had the highest strength centrality in the network. The results revealed three bridge symptoms: “psychomotor agitation/retardation”, “irritable”, and “depressed or sad mood”. Conclusion“Feeling of worthlessness” was identified as a key priority due to associations with suicidal ideation. The current study highlighted the critical central symptoms “depressed or sad mood”, “trouble relaxing” and “uncontrollable worry” and the critical bridge symptoms “psychomotor agitation/retardation”, “irritable”, and “depressed or sad mood”. Implications for clinical prevention and intervention based on these symptoms are discussed.

Factors Related to Anxiety Scores in Diabetes Mellitus Outpatients at the Universitas Sumatera Utara Hospital

Background: Diabetes mellitus (DM) is a serious chronic disease, caused by the inability of the pancreas to produce enough insulin. It is estimated that people with diabetic are at twice the risk of anxiety compared to the general population. Diabetic patients with anxiety has been related to increasing risk of comorbidities, which can interfere with daily living activities, and life quality, increased health costs, and many other complication when compared with the general population.&#x0D; Method: This study is a predictive type multivariate study, with a cross-sectional approach to 111 subjects in the outpatient clinic of Universitas Sumatera Utara hospital. The tests carried out in this study were the bivariate test, multivariate linear regression test to determine what factors are related to anxiety scores in DM patients, using the Hospital Anxiety and Depression Scale (HADS-A) as measurement tool.&#x0D; Results: After conducting the multivariate analysis test, it was found that the variables associated with anxiety scores in people with DM were length of education (p &lt;0.001), Body Mass Index (p &lt;0.001), duration of illness (p &lt;0.001), work status (p &lt;0.001), comorbidity (p = 0.021).&#x0D; Conclusion: By knowing the factors that influence anxiety scores in people with DM, it is hoped that clinicians will pay more attention to the symptoms of anxiety in people with DM, especially in the early days of diagnosis so that intervention can be carried out.

Yoga for depression and anxiety symptoms in people with cancer: A systematic review and meta-analysis.

Cancer and its treatment can lead to a variety of physical and emotional concerns impacting on those affected, including subclinical or clinical depression and anxiety, which in turn have a significant impact on wellbeing, quality of life and survival. The aim of this review was to evaluate the effect of yoga-based interventions on self-reported depression and anxiety symptoms in people with cancer in randomized controlled trials. Six databases were searched to identify relevant studies. Systematic review procedures were followed including a quality assessment. Meta-analysis of suitable studies was conducted. 26 studies from our search criteria were eligible for inclusion for depressive and 16 for anxiety symptoms. Meta-analyses revealed evidence for significant medium effects of yoga on depression symptoms (N=1,486, g=-0.419, 95% confidence interval [CI]=-0.558 to -0.281, p<0.001) and anxiety (N=977, g=-0.347, 95% CI=-0.473 to -0.221, p<0.001) compared to controls. Subgroup analyses for depressive symptoms revealed significant effects for all analyses performed (type of cancer, type of control, treatment status, duration of intervention or frequency of yoga sessions), with effect sizes being comparable between subgroups. Similar findings were found for anxiety symptoms except for treatment status, where the only significant effect was found when yoga was delivered during active treatment. This review provides evidence that in people with cancer, yoga-based interventions are associated with amelioration of depression and anxiety symptoms and therefore a promising therapeutic modality for their management. However, the potential for risk of bias together with control group design challenges means the results should be interpreted with caution.